As docetaxel is known to have significant antineoplastic activity against breast and ovarian cancer, we explored its application as a peripheral blood stem cell mobilizing agent in 33 women with stage lll-IV ovarian carcinoma (n ‫؍‬ 10) or stage ll-lV breast cancer (n ‫؍‬ 23) who were in preparation for high-dose chemotherapy. Eleven patients had bone and/or bone marrow involvement with their disease. The median number of prior regimens received before mobilization was two (range 1-3). The three dose levels administered were 100 mg/m Peripheral blood progenitor cells (PBPC) were initially harvested without prior stimulation but it is known that circulating progenitors markedly increase during the recovery phase after myelosuppressive chemotherapy. The recovery of bone marrow after chemotherapy-induced myelosuppression typically produces an abundant release of progenitor cells into the peripheral blood and the magnitude of the increase in circulating progenitor cells appears to correlate
with the intensity of the myelosuppression induced by chemotherapy. 1 Chemotherapy agents utilized for PBPC mobilization ideally produce short-term marked myelosuppression while sparing stem cells from severe toxicity. An optimal chemomobilizing agent ideally should have known antitumor activity with manageable toxicities. Docetaxel has been reported to have significant activity against advanced breast cancer and ovarian cancer including anthracycline-resistant breast cancer and platinum-refractory ovarian cancer. [2] [3] [4] [5] [6] [7] The other available taxane, paclitaxel, has been shown to be an effective PBPC mobilizer as a single agent and in combination with cyclophosphamide and etoposide, epirubicin, ifosfamide and high-dose cyclophosphamide. [8] [9] [10] [11] [12] [13] [14] [15] As single agents, both docetaxel and paclitaxel induce WBC nadirs of brief duration without severe thrombocytopenia. Docetaxel can be safely administered on an outpatient basis as it causes minimal nausea and vomiting and does not require aggressive intravenous hydration as do the more traditional chemotherapeutic mobilizing regimens involving high-dose cyclophosphamide. Grade 4 neutropenia is the dose-limiting toxicity of docetaxel. We conducted a phase II trial to determine the efficacy of docetaxel with filgrastim to mobilize PBPCs in women with epithelial ovarian cancer or with breast cancer who were scheduled to undergo high-dose chemotherapy.
Materials and methods

Patient selection
Patients with stage lll-IV epithelial ovarian cancer or women with stage ll-lV breast cancer were eligible (Table  1) . Eligibility requirements included age у18 years old, a platelet count of у100 000 ϫ 10 9 /l, absolute neutrophil count of у1.0 ϫ 10 9 /l and a CALGB performance status of 0 or 1. All patients were required to have adequate cardiac, pulmonary, renal and hepatic function. Written informed consent approved by the University of Chicago Medical Center Institutional Review Board was obtained in all cases. Patients with a history of life-threatening hypersensitivity to any taxane were excluded. Toxicities were assessed using the CALGB Toxicity Grading Criteria. 
Treatment plan
All patients had a double-lumen leukapheresis-grade vascular catheter placed at entry to the protocol. Patients were instructed to take warfarin 2 mg p.o. starting 48 h after catheter placement to prevent line thrombosis. The initial starting dose of docetaxel was 100 mg/m 2 and dose escalation occurred at 10 mg/m 2 increments up to 120 mg/m 2 . When a patient in each cohort failed to reach adequate myelosuppression as defined by grade 4 neutropenia, the next dose level was then implemented for subsequent patients.
Patients were premedicated with dexamethasone 8 mg p.o. every 12 h ϫ 5 doses starting 24 h prior to the docetaxel dose. Docetaxel was diluted in 250 ml D5W for a final concentration of 0.3-0.9 mg/ml. It was administered as a 2 h infusion in the outpatient setting and patients were observed in the clinic for at least 30 min after the infusion was completed. Four days after docetaxel administration, filgrastim (G-CSF) was given at a dose of 10 g/kg/day subcutaneously until leukapheresis was completed. Patients were given ciprofloxacin 500 mg p.o. every 12 h during the period of neutropenia as defined by a WBC of Ͻ1 ϫ 10 9 /l. Leukapheresis commenced when the WBC Ͼ1.0 ϫ 10 9 /l or when the WBC began to rise after reaching a nadir if the WBC never fell below 1.0 ϫ 10 9 /l. The target yield was у2 ϫ 10 6 CD34 ϩ cells/kg. The maximum number of leukapheresis sessions was not specified. Leukapheresis was performed using either the CS3000 blood cell separator (Baxter, Fenwal Division, Round Lake, IL, USA) or the COBE Spectra cell separator (COBE BCT, Lakewood, CO, USA). The patient's blood volume was twice processed to a maximum of 10 liters. The mononuclear cell suspension obtained by apheresis was adjusted to a cell concentration of approximately 1 ϫ 10 7 cells/ml and mixed with an equal volume of tissue culture medium containing preservativefree heparin and 20% DMSO. Fifty to 100 ml aliquots were frozen in appropriate containers at a controlled rate and stored in liquid nitrogen.
Statistical considerations
Linear relationships between dose levels and CD34 ϩ and MNC collection yields were assessed using Pearson's correlation.
Results
Patient characteristics
Between February 1997 and June 1999, 33 women with a median age of 49 years (range 32-64) with stage ll-lV breast cancer (n ϭ 23) or stage lll-IV ovarian cancer (n ϭ 10) were enrolled. Patients were eligible if they were candidates to receive high-dose chemotherapy with autologous PBPC rescue. The median number of prior regimens received before mobilization was two (range 1-3). Eleven patients had bone and/or bone marrow metastases and 15 patients had received prior radiotherapy (Table 1) .
Dose levels
The first four patients were treated at dose level 1 (100 mg/m 2 ). As the fourth patient enrolled in this cohort failed to reach grade 4 neutropenia as defined by ANC Ͻ1000, subsequent patients were enrolled at dose level 2 (110 mg/m 2 ) for a total of six patients. As the sixth patient in this cohort did not reach grade 4 neutropenia, all subsequent patients (n ϭ 23) were treated at the third and highest dose level (120 mg/m 2 ). Median blood count nadirs for each dose level are illustrated in Table 2 .
Stem cell collection and yield
Thirty-two patients (97%) began leukapheresis within 7-9 days (median 8 days) after receiving docetaxel with 23 patients (70%) commencing leukapheresis on day ϩ8 (Figure 1) . For all 33 patients, 27 (82%) reached the collection goal of у2 ϫ 10 6 CD34 ϩ cells/kg with a median 2.63 ϫ 10 6 CD34 ϩ cells/kg collected (range 0.9-8.7). Twentysix of these 27 patients reached this minimum target yield within 1-3 days with a median of 2 days. One patient reached this target yield after only 2 leukapheresis days after failing to achieve this goal with 14 previous leukapheresis days using growth factor mobilization alone on a different protocol. Of the six patients who did not reach the collection goal, two had previously failed to mobilize using a mobilization protocol with growth factor alone. All of the patients with ovarian cancer (n ϭ 10) reached the collection goal as compared to 17 of 23 patients with breast cancer (74%). Four patients yielded greater than 5 ϫ 10 6 CD34 ϩ cells/kg (range 5.83-8.74) with three of the four patients reaching this goal with one leukapheresis session and one patient requiring two leukapheresis sessions. Analyzing the results by dose level, no linear correlation was observed with increasing doses of docetaxel for both Number of leukaphereses Probability of obtaining MNC yields and stem cell yields (r ϭ 0.23 and Ϫ0.09, respectively) ( Table 3) .
Toxicities
No dose-limiting non-hematopoietic toxicities were observed at any of the dose levels. Anaphylactic or hypersensitivity reactions did not occur during or after the 2 h docetaxel infusion. Peripheral neuropathy was also not seen. Regarding hematopoietic toxicities, none of the patients experienced neutropenic fever or required blood or platelet transfusion support.
Hematopoietic recovery
Thirty-two of the 33 patients who received mobilization chemotherapy proceeded to high-dose chemotherapy with autologous PBPC transplantation. One patient declined to proceed to high-dose chemotherapy. Hematopoietic recovery data were available from 30 patients as two patients died during the transplant procedure prior to blood count recovery. The median time to platelets greater than 20 ϫ 10 9 /l and 50 ϫ 10 9 /l was 11 days (range 8-35) and 15 days (range 11-150), respectively. The median time to ANC /l was 10 days (range 9-14). One patient failed to show platelet recovery. This patient yielded only 1.0 ϫ 10 6 CD34 ϩ cells/kg after undergoing 11 leukapheresis procedures.
Discussion
Docetaxel demonstrates significant antitumor activity with limited toxicity in patients with breast and ovarian cancer, including heavily pretreated patients. Similar to paclitaxel, docetaxel does not cause significant hematologic toxicity and is not known to be damaging to stem cells. Therefore it is an effective chemotherapeutic agent for stem cell mobilization in this population of patients in the outpatient setting. In this study, over 80% of the patients reached the collection goal of у2 ϫ 10 6 CD34 ϩ cells/kg with minimal toxicity.
We employed three different dose levels in our study. Because the number of patients in the first two dose levels were small, an accurate direct comparison cannot be made between levels. The median numbers of MNCs and CD34 ϩ cells was not significantly different between the dose levels, and toxicity did not increase with increasing doses. Therefore, our highest dose of 120 mg/m 2 appeared to be a safe dose for effective mobilization.
There are few other reports utilizing single-agent docetaxel in the mobilization setting. A recent abstract by Borges et al 16 utilized single agent docetaxel ϩ GCSF as a mobilizing agent. Nineteen patients with breast cancer received docetaxel at a dose of 100 mg/m 2 with G-CSF support. Leukapheresis was arbitrarily commenced on day ϩ8 for all patients and continued until the CD34 collection goal was reached or for a maximum of 8 days. The mean total CD34/kg obtained was 8.59 ϫ 10 6 which was higher than our mean value of 2.9 ϫ 10 6 CD34 ϩ cells/kg although the predetermined CD34 ϩ goal was not reported. Toxicity was minimal in that study as only 1/19 patients required hospitalization for febrile neutropenia. Prince et al 17 administered docetaxel (100 mg/m 2 ) and G-CSF (10 g/kg/day) to 26 women with breast cancer. A collection exceeding 5 ϫ 10 6 CD34 ϩ cells/kg in 1 apheresis day was obtained in 15 patients. Twenty-two of 26 patients (85%) achieved the minimum target collection goal of Ͼ4.5 ϫ 10 6 CD34 ϩ cells/kg with one cycle of mobilization with two additional patients reaching the target CD34 ϩ yield with a subsequent cycle of docetaxel. Only four patients in our study reached a collection goal of Ͼ5 ϫ 10 6 CD34 ϩ cells/kg but our patients were more heavily pretreated. Seventy-three percent of our patients as compared to 27% of the patients in the report by Prince et al trial had received у2 prior chemotherapy regimens.
Another advantage of this regimen was the narrow range of leukapheresis start day which allowed reliable predictability of commencing leukapheresis. Our trial and the report by Prince et al both demonstrated that day ϩ8 after docetaxel administration appeared to be the optimal time to start apheresis. In our study, 30 patients (97%) started leukaphereses within 7-9 days with 22 of 31 (71%) patients beginning on day ϩ8. Using peripheral blood CD34 ϩ enumeration to guide leukapheresis, 16 patients (62%) in the report by Prince et al 17 began apheresis on day ϩ8 when the peripheral blood CD34 ϩ cell count exceeded 5 ϫ 10 6 /l. Although peripheral blood CD34 ϩ cell counts have been established as a reliable guide to commence leukapheresis, 18, 19 this additional knowledge may be useful when the peripheral blood CD34 ϩ cells/l is not readily available or if peripheral blood CD34 ϩ results cannot be obtained in a timely manner.
Single-agent paclitaxel as a chemomobilizing agent also yields similar results with acceptable toxicities. GomezEspuch et al 10 utilized single agent paclitaxel with G-CSF as a mobilization regimen in women with breast cancer and compared toxicities and results using the same regimen with the addition of cyclophosphamide (4 g/m 2 ). 10 Patients in the former group experienced fewer days of neutropenia and thrombocytopenia than did the group that received the Table 4 Taxane-based chemomobilization regimens cyclophosphamide-containing regimen. Additionally, transfusion support and hospitalizations for neutropenic fevers were seen in the latter group only. Burtness et al 8 used single-agent paclitaxel ϩ G-CSF as a mobilizing regimen in breast cancer patients. This was a dose escalation phase I study using paclitaxel doses from 225 to 300 mg/m 2 . Despite the variability of the doses, 97% of the patients began leukapheresis during the same narrow time period of 7-9 days with 19 of 24 (79%) patients reaching the collection goal of у2.5 ϫ 10 6 CD34 ϩ cells/kg. There are currently more studies in the literature combining taxane and cyclophosphamide than utilizing single agent taxane. Table 4 summarizes the recent trials to date of taxane-containing mobilization regimens. The median CD34 ϩ yields collected did not appear to significantly increase with the addition of cyclophosphamide, nor did the median number of apheresis sessions decrease to reach the collection goal of each respective study. Table 4 also illustrates that when cyclophosphamide is added to taxane, the median leukapheresis start day was consistently Ͼ10 days with a much wider range, thus yielding less reliability in predicting leukapheresis commencement. During the mobilization process, accurate timing of leukapheresis is important to maximize stem cell yield and to minimize the number of leukapheresis sessions. However, the potential benefit with the addition of cyclophosphamide may be greater tumor cytoreduction compared to single-agent taxane.
In contrast to the mobilization schedules involving cyclophosphamide, docetaxel is associated with only mild thrombocytopenia and neutropenia. Mobilization with taxane also does not carry the potential cardiotoxicity or the risk of hemorrhagic cystitis seen with cyclophosphamide-containing regimens. This schedule may also be less costly as compared to cyclophosphamide regimens since intravenous hydration, mesna use, continuous bladder irrigation and hospitalization are not routinely required. Compared to mobilization regimens using growth factors alone, this regimen also yields the added benefit of potential tumor cytoreduction without a significant increase in side-effects for patients with breast and ovarian cancer.
In conclusion, docetaxel as a single agent at a dose of up to 120 mg/m 2 in association with G-CSF is an effective, outpatient chemomobilizing agent for patients with breast and ovarian cancer. This mobilization regimen allows reliable predictability in commencing leukapheresis with minimal toxicities and with a relative ease of administration.
